Lafutidine (FRG-8813) is a new H2-receptorantagonist that not only has a strong inhibitory effect on gastric secretion but also augments the gastric mucosa protection factor and dilate arterious, but not venules, in the gastric submucosa and enhances gastric mucosal blood flow via capusaicin-sensitive afferent neurons.
Presence in the tongue, too, suggests that lafutidine may also be effective for patients diagnosed with glossodynia. Lafutidine was administered in a dose of 10mg twice daily to 3 glossodynia patients, and reduced the tongue pain in all three.
The results confirmed the effectiveness, safety and utility of lafutidine in the treatment of glossodynia.